Revolution in the US. Trump announces the most important regulation of the decade, lowering drug prices

Donald Trump is once again attacking pharmaceutical giants and announcing a revolution that he claims could change the face of American healthcare. On the Truth Social platform, he announced that he will sign an order that will equalize drug prices in the US with those in the cheapest countries in the world. "For the first time in years, we will give America honesty," the president thunders.

Trump doesn't mince his words: "For years, the world has wondered why the same drugs, produced by the same companies, in the same factories, are many times more expensive in the United States than anywhere else. The answer? Lack of logic and greed of corporations."

The solution? Introducing the “most favored nation” principle, which requires the United States to pay the same for drugs as the country with the lowest price in the world. That means potential savings of tens of billions of dollars and, according to Trump, cuts in drug prices by as much as 80%.

As reported by Reuters, the changes would mainly apply to drugs reimbursed under the Medicare program. It would not be the first time Trump has tried to push through a similar regulation – during his first term, such plans were blocked by a court.

Americans currently spend about $400 billion a year on drugs. According to estimates, the proposed changes could reduce that cost by as much as $85 billion.

Trump does not hide the fact that the fight against pharmaceutical companies is also a blow to political connections. "Election donations can work wonders, but not with me and not with the Republican Party. We will do what is right," he wrote.

He announced that he would sign the order at the White House, promptly at 9:00 a.m. "This will be a historic moment. After years of injustice, the United States will finally stop being the cash cow of the global pharmaceutical industry," he said.

Will there really be a breakthrough this time? Will Trump's grand plan survive the clash with the courts, Congress and industry giants? One thing is certain - billions and political futures are at stake.